PD50-03 DURABLE EFFICACY AND SAFETY OF LONG-TERM ONCE-DAILY VIBEGRON, A NOVEL ORAL β-3 ADRENERGIC RECEPTOR AGONIST: A 52-WEEK PHASE 2 STUDY IN PATIENTS WITH OVERACTIVE BLADDER SYNDROME